Inferra AIResearch Tools

Inferra AI / Company / SMMT

Summit Therapeutics Inc.

SMMT · Health Care

No earnings release for Summit Therapeutics Inc. is held in this edition of the library, so no earnings line is shown.

AI analysis

Latest earnings event · reported Sep 29, 2026

Based on: Earnings release + parent 8-K — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Summit Therapeutics Inc. — Earnings release (2026-09-29)

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

htm EX-99.1 EX-99.1 Exhibit 99.1 AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit s Common Stock of $18.36, Representing a Premium over Today s Closing Trading Price Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers Summit & AstraZeneca Plan to Enter into a Clinical Trial Collaboration Combining Ivonescimab with Multiple AstraZeneca ADCs and Other Cancer Medicines Miami, Florida, September 28, 2026 Summit Therapeutics Inc.

SEC original ↗Summit Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Sep 29, 2026

Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve).

SEC original ↗Summit Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Sep 29, 2026

We are proud to welcome AstraZeneca as a strategic investor as we continue to work with purposeful urgency to make a significant difference for patients with cancer by improving outcomes.

SEC original ↗Summit Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Sep 29, 2026

A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumor types with combinations alongside next-generation immunotherapies, said Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca.

SEC original ↗Summit Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Sep 29, 2026

is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

SEC original ↗Summit Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Sep 29, 2026

Risks & headwinds

Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab.

SEC original ↗Summit Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Sep 29, 2026

Documents

Earnings deck slides

0 decks with slide view

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Summit Therapeutics Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

35 documents

Earnings releases

6 documents

Presentations

9 documents

Transcripts

0 documents

No transcripts for Summit Therapeutics Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.